ATE270545T1 - Verwendung von nmda antagonisten zur behandlung des reizkolons - Google Patents

Verwendung von nmda antagonisten zur behandlung des reizkolons

Info

Publication number
ATE270545T1
ATE270545T1 AT99947024T AT99947024T ATE270545T1 AT E270545 T1 ATE270545 T1 AT E270545T1 AT 99947024 T AT99947024 T AT 99947024T AT 99947024 T AT99947024 T AT 99947024T AT E270545 T1 ATE270545 T1 AT E270545T1
Authority
AT
Austria
Prior art keywords
nmda antagonists
irritable colon
treat irritable
treat
colon
Prior art date
Application number
AT99947024T
Other languages
English (en)
Inventor
Aziz Asghar
Jose Luis Cabero
Andrew Astrazeneca Dray
Anne King
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9801494A external-priority patent/SE9801494D0/xx
Priority claimed from SE9803954A external-priority patent/SE9803954D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE270545T1 publication Critical patent/ATE270545T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
AT99947024T 1998-04-28 1999-04-28 Verwendung von nmda antagonisten zur behandlung des reizkolons ATE270545T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9801494A SE9801494D0 (sv) 1998-04-28 1998-04-28 Novel use
SE9803954A SE9803954D0 (sv) 1998-11-18 1998-11-18 Novel use
PCT/SE1999/000702 WO1999055323A1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
ATE270545T1 true ATE270545T1 (de) 2004-07-15

Family

ID=26663287

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99947024T ATE270545T1 (de) 1998-04-28 1999-04-28 Verwendung von nmda antagonisten zur behandlung des reizkolons

Country Status (20)

Country Link
EP (1) EP1073431B1 (de)
JP (1) JP2002512956A (de)
KR (1) KR100569777B1 (de)
CN (1) CN1200702C (de)
AR (1) AR016212A1 (de)
AT (1) ATE270545T1 (de)
AU (1) AU760783B2 (de)
BR (1) BR9909971A (de)
CA (1) CA2329328A1 (de)
DE (1) DE69918541T2 (de)
DK (1) DK1073431T3 (de)
ES (1) ES2221753T3 (de)
IL (1) IL138919A0 (de)
MY (1) MY121063A (de)
NO (1) NO20005386D0 (de)
NZ (1) NZ507436A (de)
PT (1) PT1073431E (de)
SA (1) SA99200482B1 (de)
TW (1) TW570793B (de)
WO (1) WO1999055323A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5042425B2 (ja) * 2000-03-01 2012-10-03 ユーロセルティック ソシエテ アノニム 機能性胃腸疾患治療用トラマドール
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
JP2003081872A (ja) * 2001-09-13 2003-03-19 Nippon Oruganon Kk 掻痒治療薬
NZ542260A (en) * 2003-03-14 2009-03-31 Agi Therapeutics Res Ltd Treatment of intestinal conditions with mecamylamine
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
FR2865133B1 (fr) * 2004-01-19 2008-01-18 Rytek Compositions pour le traitement de pathologies digestives
CA3105834A1 (en) * 2018-07-06 2020-01-09 Algernon Pharmaceuticals Inc. Compounds for treatment of inflammatory bowel disease and methods thereof
KR102211282B1 (ko) 2019-11-20 2021-02-03 (주)파이브텍 데이터 라우팅 방법 및 이를 지원하는 스위치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition

Also Published As

Publication number Publication date
NZ507436A (en) 2003-09-26
NO20005386L (no) 2000-10-26
SA99200482B1 (ar) 2006-06-27
AU4302499A (en) 1999-11-16
PT1073431E (pt) 2004-10-29
DE69918541T2 (de) 2005-08-18
WO1999055323A1 (en) 1999-11-04
EP1073431A1 (de) 2001-02-07
CA2329328A1 (en) 1999-11-04
JP2002512956A (ja) 2002-05-08
BR9909971A (pt) 2000-12-26
CN1307471A (zh) 2001-08-08
TW570793B (en) 2004-01-11
AR016212A1 (es) 2001-06-20
AU760783B2 (en) 2003-05-22
EP1073431B1 (de) 2004-07-07
DK1073431T3 (da) 2004-10-04
NO20005386D0 (no) 2000-10-26
HK1033876A1 (en) 2001-09-28
CN1200702C (zh) 2005-05-11
KR100569777B1 (ko) 2006-04-11
KR20010043077A (ko) 2001-05-25
MY121063A (en) 2005-12-30
ES2221753T3 (es) 2005-01-01
DE69918541D1 (de) 2004-08-12
IL138919A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69722681D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69836915D1 (de) Mundpflegemittel zur behandlung von übelriechendem atem
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
ATE323661T1 (de) Behandlung von mineralischen stoffen
ATE300597T1 (de) Behandlung von geweben
EP1240280A4 (de) Behandlung von kohle
ATE353218T1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
DE69625877D1 (de) Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
ATE301703T1 (de) Verwendung von zusammensetzungen zur textilpflege
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE339955T1 (de) Verwendung von escitalopram zur behandlung von generalisierten angstzuständen
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
DE69621447D1 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
ATE326969T1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
ATE261304T1 (de) Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE60103503D1 (de) Verwendung von fsh zur behandlung von infertilität
ATE317261T1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1073431

Country of ref document: EP

REN Ceased due to non-payment of the annual fee